Pfizer signs licence agreement with Chai for AI drug discovery
This partnership provides the biopharmaceutical company with early access to the Chai-3 model alongside a dedicated model tailored to Pfizer’s proprietary data and workflows, underscoring a strategic move
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.